Cn /En

News Center

——

Company news

Industry news

InnoModels Biotechnology: iHuPDX Platform Feature Presentation

Author:

InnoModels

Release time:

2024-06-18

With its unique iHuPDX platform, InnoModels Biotechnology has opened a whole new chapter in tumor research and clinical applications. The platform builds highly individualized disease models based on individual patient's tumor cells, which not only helps to understand the patient's tumor characteristics more comprehensively, but also provides strong support for precision medicine and the development of personalized treatment plans. In this article, we will introduce the main features of the iHuPDX platform of InnoModels Biotechnology in detail.
Firstly, the iHuPDX platform stands out for its excellent stability and growth rate. With the help of primary cell inoculation technology, the platform successfully creates an unparalleled pharmacodynamic model. This model is characterized by its cell suspension modeling approach, which ensures homogenization of samples between batches. This means that samples from the same batch maintain a high degree of consistency in growth rate and biological characteristics, thus laying a solid foundation for model stability. At the same time, homogenized samples from the same batch also ensure the stability in the same generation and after the transmission, which enables the model to maintain consistent growth and efficacy characteristics in long-term studies, providing a strong guarantee for the reliability of the experimental results.
Secondly, the iHuPDX platform realizes uniform growth at an early stage, providing an ideal experimental window for potency experiments. Efficacy experiments are usually conducted in P2-P5 generations, avoiding the problems of property changes and model wastage caused by multiple passages. In addition, the group residual can be reduced to 20% without compromising the quality of the experiment, thus significantly reducing the cost of the experiment. This feature makes the iHuPDX platform more attractive for drug discovery and clinical application.

In addition to stability and growth rate, the iHuPDX platform also has the ability to construct individualized disease models. Based on an individual patient's tumor cells, the platform is able to build highly individualized disease models. This helps researchers gain a more comprehensive understanding of a patient's tumor characteristics, including their unique genetic mutations, phenotype and biological behavior. Through comparative analysis of tumor models from different patients, researchers can reveal heterogeneous differences between tumors and provide strong support for the development of precision medicine.
In addition, the iHuPDX platform can be used for drug response prediction. Due to its highly individualized nature, the platform is able to simulate the response of a specific patient's tumor to a drug. This allows researchers to screen and evaluate multiple drugs in the lab to find the most effective treatment option for a specific patient. This ability to predict drug response is important for improving treatment success, reducing unwanted side effects, and lowering healthcare costs.
Finally, it is worth mentioning that the iHuPDX platform can also be combined with a humanized model of the PBMC immune system to provide ideal experimental conditions for tumor immunity research. By combining the tumor model with the immune system model, researchers can explore the interactions between tumors and the immune system in greater depth, providing important clues for the development of more effective immunotherapy strategies.
In summary, the iHuPDX platform of InnoModels Biotechnology has shown great potential in the field of tumor research and clinical applications with its stability, growth rate, ability to construct individualized disease models, and drug response prediction. With the continuous development and improvement of this platform, it is believed that it will bring more breakthroughs and innovations in tumor treatment in the future.

InnoModels Biotechnology: Characteristics and Application Prospects of 3D Organoid Platforms

InnoModels Biotechnology: Explaining the Features and Value of the FACS Platform

InnoModels Biotechnology: Characteristics and Application Prospects of 3D Organoid Platforms

InnoModels Biotechnology: Explaining the Features and Value of the FACS Platform

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License